Navigation Links
China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013

g excited to see positive response in the start-up phase of our Zhejiang operation.  We are pleased with the achievements that we have made and excited by the vast opportunities ahead of us.  We will strive to achieve our medium- to long-term corporate objectives by continuously refining our marketing strategies, quality standards, and operational strategy, and in turn, maximizing corporate value and return to our shareholders." 

[1] The terms of the convertible notes issued to KKR and Golden Meditech provide KKR and Golden Meditech with the ability to participate in any excess cash dividend. Therefore, the calculation of basic EPS has taken into consideration of such participating rights effect of RMB0.05 ($0.01) and RMB0.08 ($0.01) for the three months and nine months ended December 31, 2012, respectively.

[2] "Excess Cash Dividend" means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant record date.

Conference CallThe Company will host a conference call at 8:00 a.m. ET on Wednesday, February 27, 2013 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.  Interested parties may access the audio webcast through the Company's IR website at  A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above.  Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers,

SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
2. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
3. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
4. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
5. China Cord Blood Corporation to Further Consolidate its Corporate Structure
6. Biomaterials China News 1210 - Annual Subscription
7. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
8. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
10. China Biologic Products to Report Third Quarter 2012 Financial Results
11. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
Post Your Comments:
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... oncology company developing new treatments for cancer and ... Chief Executive Officer, will be presenting at the ... Las Vegas :Event:Aegis Capital Corporation 2015 ... PDTLocation:Brahms 2 room, The Encore @ The Wynn ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, today announced its schedule ... place in the month of October: Stem ... RepliCel will be presenting at the annual Partnering Forum, ... to be held October 7-9 in La ...
Breaking Biology Technology:
... sole U.S. supplier of 3M electrosurgical grounding pads ... ... Industries, Inc. and,3M Health Care announce an exclusive license and supply ... agreement,Medline has acquired the exclusive license and sales rights in the ...
... Eastern Time Today, GAITHERSBURG, Md., March 6 ... and corporate progress for,the full year ended December 31, ... further demonstrated that Iomai,s,vaccine and immunostimulant patches can be ... chief executive officer,of Iomai. "This lays the foundation for ...
... (Pink Sheets: VXGN), a biopharmaceutical company, today reported its,year ... a view to,ensuring that stockholders have the most current ... with Raven biotechnologies,inc. VaxGen,s Board of Directors has set ... of Stockholders to vote on the proposed merger., ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
... and Nanosystems Research (IBN), Austrian Academy of Sciences ... of Technology, Cambridge, USA report the study of ... Designer Lipid-Like Peptide Surfactants” in the May 30th ... Their findings not only help us to ...
... a chronic and progressive lung disorder from which most patients ... by the insidious onset of dyspnea or cough and usually ... coworkers present in an article published in the online, open-access ... that a subset of IPF patients has a short duration ...
... chronic lung disease typically characterized by the slow but ... patients live about five years after diagnosis. However, according ... online journal PLoS ONE, a subset of patients with ... progression to complete pulmonary failure and death without a ...
Cached Biology News: